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Major depressive disorder is one of the most
common psychiatric disorders, with a worldwide
lifetime prevalence rate of 10%–20% in women
and a slightly lower rate in men. While many
patients are successfully treated using established
therapeutic strategies, a significant percentage of
patients fail to respond. This report describes the
successful recovery of a previously treatment-
resistant patient following right unilateral deep
brain stimulation of Brodmann’s area 25. Cur-
rent therapeutic approaches to treatment-resistant
patients are reviewed in the context of this case
with an emphasis on the role of the right and left
hemispheres in mediating disease pathogenesis
and clinical recovery.
(The Journal of Neuropsychiatry and Clinical
Neurosciences 2010; 22:265–277)
Mr. A, a right-handed man of Austrian-Argentinedescent who was 60 years old at the time of his
first visit to our tertiary center, had been referred for
evaluation of his chronic treatment-resistant depres-
sion. The patient presented with his first major depres-
sive disorder episode at age 39, which was not related
to an obvious significant life stressor. Mr. A had a fam-
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ily history of both documented affective disorder and
other less well characterized illnesses in his first- and
second-degree relatives. Mr. A’s paternal grandfather
had spent time in a psychiatric hospital in Europe for
unknown reasons but possibly related to his participa-
tion in World War I, and his sister had been diagnosed
with depression which responded to antidepressants.
Mr. A’s first depressive episode was successfully
treated with a tricyclic antidepressant, which was dis-
continued after 1 year. Mr. A remained symptom-free
until he was 49 years old, when a second severe, non-
psychotic major depressive episode developed approx-
imately 4 months after the detection and successful sur-
gical resection of a localized prostate cancer. Symptoms
were sustained (although with some fluctuations in se-
verity lasting a few months) with little to no response to
various treatments including paroxetine, fluoxetine,
sertraline, mirtazapine, and clomipramine prescribed at
maximal doses and taken for sufficient duration. Some
of these antidepressants were augmented with lithium,
divalproex sodium, risperidone, or olanzapine without
benefit. Supportive psychotherapy was provided
throughout the episode combined with a formal trial of
cognitive behavior therapy (CBT), again without clini-
cal benefit.
The patient was referred for consultation to our cen-
ter after 10 years, at age 60. At the time of first evalua-
tion, the patient had been unemployed for 3 years, was
receiving disability benefits, and had experienced a loss
of 17 kg in the previous 6 months. Neurological and
medical examinations were normal. On mental status
examination the patient appeared as a thin 60-year-old
male, looking older than his stated age, disheveled,
with poor self-care and grooming, no abnormal move-
ments, and coherent but slow and impoverished
speech. His thought content was focused on overvalued
ideas of financial ruin. The patient was not suicidal. His
mood was self-described as “horrible” and his affective
expression was flat and congruent with the reported
mood. He had no hallucinations in any sensory modal-
ity, Schneiderian first-rank symptoms, passivity experi-
ences, obsessions, compulsions, phobias, depersonal-
ization, or derealization. He retained insight into the
nature of his health problem and his judgment was
appropriate. A new medication regimen was instituted
and included extended-release venlafaxine, 225 mg p.o.
daily, and quetiapine, 200 mg p.o. twice daily, which
remains unchanged to this day. A course of CBT was
also initiated, but the patient was unable to comply
with therapy demands due to poor attention and low
energy.
Given continued severe symptoms, failure of stan-
dard and combination pharmacotherapy and psycho-
therapy, and absence of any neurological contraindica-
tions, ECT, a relatively seldom used treatment in his
cultural setting, was considered for this patient. The
patient underwent a series of 15 bilateral ECT sessions
with seizure duration between 28 and 55 seconds. This
ECT course brought about a mild and short-lived sub-
jective amelioration; mood, initiative, sleep, and appe-
tite modestly improved. The patient and his family
deemed this improvement unsatisfactory.
Mr. A regressed to his previous level of symptom
severity approximately 6 weeks after the last ECT ses-
sion, in spite of continued treatment with venlafaxine,
225 mg per day, and quetiapine, 200 mg twice a day, as
stated above. He had subjective complaints of attention
and memory difficulties and these worsened transiently
after the ECT course. Both the patient and his family felt
the mild improvement in symptoms did not warrant a
further course of ECT or maintenance ECT sessions. As
recommended by a team meeting in the psychiatry de-
partment, the patient and his family were then offered
deep-brain stimulation (DBS) of white matter immedi-
ately adjacent to Brodmann’s cortical area 25 (Cg25-
DBS, subgenual cingulum) bilaterally as an experimen-
tal treatment for refractory depression that had shown
promise in a recently published case series.1 This pro-
cedure was offered instead of other neurosurgical op-
tions such as ablations or vagus nerve stimulation be-
cause of the extensive experience in our center (i.e.,
200 interventions) with the use of DBS as a treatment
of idiopathic Parkinson’s disease. Written consent was
obtained from the patient and his wife. The protocol
and consent form were modified from the original Ca-
nadian Cg25-DBS pilot study1 and explicitly stated that
the procedure was experimental, requiring testing of
different stimulation parameters to optimize potential
clinical effects and to minimize adverse events. Prior to
the procedure, the approval by the local bioethics com-
mittee, the signed consent form, a summary of the pa-
tient’s history, and the technical description of the
device were all reviewed—and approved—by the Ar-
gentine National Administration on Medications and
Medical Devices (ANMAT), the national government
agency regulating the local use of experimental drugs
and medical devices. The patient was implanted as pre-
viously described.1
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With the patient awake, different contact patterns
were probed in the operating room, and some patterns
consistently produced a sense of well-being that the
patient described as “a relief of the tension in my neck.”
After the operation, additional systematic testing of dif-
ferent pairs of bilateral and symmetrical contacts at
varying current settings was performed in the first 3
days while in the hospital (contacts were changed every
3 hours during the daytime). Initial stimulation param-
eters were selected based on the Canadian pilot study1,2
(voltage 1.5 V, pulse width 70 sec, and frequency 90
Hz), and all these parameters were titrated upward to a
maximum of 6 V, 90 sec, and 130 Hz for each pair of
electrodes at the aforementioned time. Testing of dif-
ferent combinations of contacts and currents continued
in an outpatient setting, with evaluations and changes
performed every 2 weeks. Response to each pattern of
stimulation was based upon the subjective account of-
fered by the patient while in the hospital, and then by
means of the Beck Depression Inventory (BDI) and 21-
item Hamilton Depression Scale (HAM-D), as depicted
in Figure 1. This process continued for 6 months with
stimulation parameters in electrodes 2 (left hemisphere)
and 6 (right hemisphere) associated with the most con-
sistent symptom amelioration: frequency 120 Hz, pulse-
width 90 sec, and voltage 4.5 V. After 6 months, the
patient’s improvement reached a plateau, despite an
initial and sustained drop in both Hamilton and BDI
scores (see Table 1, Figure 1). Further adjustments did
not facilitate additional change in scores, which re-
mained stable. As such, at 12 months and based on
literature data suggesting a differential contribution of
the left and right hemispheres to mood regulation, we
began testing unilateral Cg25-DBS with those stimula-
tion parameters found to be optimal in bilateral stimu-
lation with the purpose of pursuing complete remission
of depressive symptomatology. As shown in Figure 1,
left unilateral (L) stimulation appeared to be followed
by rapid (i.e., less than 1 week) worsening of mood. At
the next appointment (2 weeks later), Mr. A actually








MMSE 30 29 30 27
ACE 92 93 95 90
Rey’s Verbal-Auditory Learning
Total score 29 44 37 37.69.8
Delayed 5 7 11 6.83.7
Recognition 13 12 13 10.13.3
Boston Naming Test 19 20 20 18
Phonological Fluency 10 13 16 14.53.8
Semantic Fluency 17 12 18 18.24.2
Forward Digits 6 7 6 5
Backward Digits 4 6 4 4
Trail-Making test, part A (S) 37 32 25 35.811.9
Trail-Making test, part B (S) 90 60 63 81.238.5
WCST 6/6 6/6 6/6 5/6
Rey-Osterrieth Complex Figure
Copy 36 36 34 30.84.2
Long-term recall 15 25 23 14.27.5
Logical-Visual Reasoning (WAIS Matrices) 15 17 16 12
MMSEMini-Mental State Examination; ACEAddenbrooke’s Cognitive Examination; WCSTWisconsin Card Sorting Test;
WAISWeschler’s Adult Intelligence Scale
FIGURE 1. Depressive Symptom Course After Bilateral, Left (L)
and Right (R) Unilateral Deep-Brain Stimulation of






















J Neuropsychiatry Clin Neurosci 22:3, Summer 2010 http://neuro.psychiatryonline.org 267
stated “by the time I reached the elevators, I was not
feeling well already.” Even though, as depicted in Fig-
ure 1, the patient did not return to his preoperative
degree of depressive symptomatology, per his subjec-
tive account of mood, feelings of inner tension, and
anergia, his status was distinctly different than experi-
enced with bilateral stimulation, beginning within the
hour of changing stimulation parameters. At this point,
settings were switched to right unilateral stimulation
(R, Figure 1), which, in contrast to left unilateral stim-
ulation, resulted in not only reversal of the new symp-
toms but improvement beyond that seen with bilateral
stimulation. With right unilateral stimulation, consis-
tent remission of symptoms was seen within 2 weeks,
both as rated by the patient with the BDI and as directly
observed by the psychiatrist and quantified with the
HAM-D. Mr. A was made aware by staff when stimu-
lation parameters were being changed, but he remained
blind to what these parameters were, and if stimulation
was bilateral, right, or left. The psychiatrist who con-
ducted the rating was not blind to these changes.
Retesting of left unilateral stimulation performed
with the purpose of ruling out a placebo effect or a
temporary worsening unrelated to the type of stimula-
tion resulted in similar transient worsening of symp-
toms within hours (Figure 1) and similar accounts of
deterioration in mood, anxiety, and lack of energy,
whereas reinstitution of right unilateral stimulation
brought about full symptom remission within 4 weeks
that continues to the present time (now over 12 months
later). No washout periods with stimulators off, or re-
sumption of bilateral stimulation, were used when
changing unilateral stimulation from one side to the
other. No further trials were conducted because the
patient remains fully remitted on unilateral right stim-
ulation at 120 Hz, 90 sec, and 4.5 V.
Overall, the surgical procedure and testing of all con-
tacts at the various parameters was generally well tol-
erated. There were no behavioral or cognitive adverse
events at any settings (Table 1), and unilateral stimula-
tion was not associated with cognitive symptoms. How-
ever, initial postoperative testing of the most proximal
electrodes (bilateral stimulation, 120 Hz, 90 sec, 3 V at
contacts 3 and 7; i.e., those lying immediately adjacent
to subcallosal cingulate gray matter) resulted in no
change in mood symptoms but acute onset of ortho-
static hypotension that normalized immediately when
stimulation was discontinued. Such autonomic changes
were seen at no other contacts. Retest of the deepest elec-
trodes bilaterally 6 months postoperatively was per-
formed because prior orthostatism could have been re-
lated to the postoperative status. With repeat testing,
reversible asymptomatic, albeit significant (15 mmHg),
decrease in mean arterial pressure was induced within 60
seconds of stimulation onset. Unilateral stimulation using
these contacts was not performed.
DISCUSSION
Major depressive disorder is the leading cause of dis-
ability-adjusted life years lost for people ages 15–44
years old worldwide.2 Although the etiology of depres-
sion remains relatively obscure, the available evidence
suggests that major depressive disorder is a complex
disorder that results from an interaction of biological,
genetic, psychosocial, and environmental factors.3
Functional neuroimaging studies have broadened our
understanding of how these complex factors impact the
CNS to produce major depressive disorder symptoms4,5
and how various treatments mediate recovery.6–9 Bilat-
eral deep brain stimulation of the white matter imme-
diately beneath the subcallosal cingulate was in fact
developed based upon the results of such studies,1 and
is currently being investigated as a potential treatment
option for patients who fail to respond to approved
methods for management of treatment-resistant depres-
sion.10
A critical issue in the management of this case was
the criteria used both to define treatment resistance and
as a foundation for offering a potential new treatment
of yet unproven efficacy. Treatment-resistant depres-
sion has been traditionally defined as an inadequate
response to an adequate course of treatment in a patient
with major depressive disorder.11 Opinions vary re-
garding precisely what constitutes an inadequate re-
sponse. Thase and Rush12 proposed a five-stage system
for defining treatment-resistant depression, which
ranges from lack of response to a single adequate trial
of antidepressants to lack of response to ECT, the most
effective single treatment for depression.13,14 Reported
prevalence rates for treatment-resistant depression vary
according to which criterion is used to define the con-
dition and the clinical setting in which the study was
carried out, with progressively higher rates occurring in
ambulatory settings, psychiatric hospitals, and tertiary
care settings. Our patient would clearly meet Stage 5
treatment-resistant depression, defined as failure to re-
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spond to three antidepressants and failure to respond to
ECT.11 This condition, as exemplified by our patient, is
associated with a remarkable burden in direct and in-
direct costs, in loss of quality of life for patients and
their families, and in increased risk for suicide and
substance abuse.15–17 While multiple factors are known
to contribute to treatment nonresponse among individ-
uals with major depressive disorder, the two most com-
mon causes—poor adherence to prescribed treatment18
and poor tolerability19,20—were not at issue here. Chro-
nicity of depression (in terms of duration of the present
episode and number of previous episodes), older age,
psychiatric and medical comorbidities, and symptom
severity are all associated with delayed time to remis-
sion12,21,22 and were serious considerations in this case.
It is well recognized that medical and psychiatric co-
morbidities can play a crucial role in treatment resis-
tance. In STAR*D, 53% of patients had one or more
significant medical comorbidities. Older age, lower so-
cioeconomic and educational status, and lack of a fam-
ily history of depression were additionally associated
with this complicating factor23 and contributed to treat-
ment resistance. In this case, there were no such comor-
bid factors except for the inactive prostate cancer.
The steps taken in the treatment of Mr. A when his
depressive symptoms failed to respond to efficacious
treatments reflect the usual practice in the management
of treatment-resistant depression, though, as noted
above, there is a remarkable paucity of well-controlled
and adequately powered studies comparing different
treatment options to manage advanced-stage treat-
ment-resistant depression.11 Increasing antidepressant
dose switching or combining with a second class of
antidepressant, augmentation strategies (with lithium,
T3, or an atypical antipsychotic), and an adequate
course of ECT are the usual steps to manage treatment-
resistant depression and were tried in succession with
Mr. A, albeit unsuccessfully. Mr. A’s case is an example
of a significant number of patients who remain seri-
ously ill despite currently available approaches to treat-
ment-resistant depression. A major shortcoming in the
treatment of depression in general, but in treatment-
resistant depression specifically, is the lack of predictors
of response to particular treatments in individual pa-
tients.24 In the last decade, functional brain imaging
techniques have begun to delineate the putative brain
circuits that are altered in depression, and the func-
tional brain correlates of antidepressant treatment non-
response.25–27 These research efforts have prompted the
design of interventions that attempt direct modulation
of abnormal circuits for alleviation of otherwise refrac-
tory depressive symptoms.5
Brain Circuits Involved in Depression and Deep Brain
Stimulation of Brodmann’s Area 25
A brain circuit model explaining the development, re-
sponse to treatment, and neurobiological basis of treat-
ment nonresponse in depression maintains the classical
neurological tradition of symptom localization, initially
using lesion-deficit correlational analyses.5 Before the
advent of widely available functional brain imaging
techniques, the study of the effect of discrete brain le-
sions helped to delineate areas putatively involved in
the onset of depressive symptoms. With the help of
those studies, the prefrontal cortex (PFC) and different
cerebral structures interconnected with it have long
been recognized as key brain areas in the pathogenesis
of depression. The last decade witnessed a myriad of
studies that used functional brain imaging techniques
with increasingly better anatomical resolution to define
the role of cortical and subcortical brain areas involved
in the development, maintenance, response to treat-
ment, and treatment-refractoriness of depressive ill-
ness.5–9,26,27
Concordant with the results of lesion studies, resting-
state blood flow and glucose metabolism measures us-
ing PET commonly reported frontal cortex and cingu-
late abnormalities, especially decreased function.8,28
Within the frontal lobe, the most consistent abnormali-
ties have been found in ventrolateral and dorsolateral
prefrontal cortex (Brodmann’s areas 9, 10, 46, and 47),
as well as orbitofrontal and ventromedial PFC (Brod-
mann’s areas 10, 11, and 32). Less consistent abnormal-
ities have been reported for limbic and subcortical
structures, including amygdala, anterior temporal and
insular cortices, and sections of the basal ganglia and
thalamus.5 Both bilateral and asymmetrical findings
have been reported. Although some functional neuro-
imaging findings are consistent, others display signifi-
cant interindividual variability, possibly related to dif-
ferences in genetic predisposition, early life adverse
experiences, heterogeneity in clinical presentation, ill-
ness severity, and cognitive dysfunction. A replicated
observation in these resting-state studies has been the
inverse relationship between PFC activity and depres-
sion severity. Brody and coworkers29 have proposed a
more complex relationship between behavioral abnor-
malities and cerebral activity in depression, in the form
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of a ventral-dorsal segregation of PFC functions. In this
view, anxiety/tension is positively correlated with
ventral PFC activity, and psychomotor and cognitive
slowing are negatively correlated with dorsolateral
PFC activity, findings supported in viewing brain
imaging studies that compare major depression and
generalized anxiety disorder.30
Functional neuroimaging studies that explore the
neurobiological basis of response and refractoriness to
diverse treatments for depression are of particular im-
portance in the definition of potential targets for direct
modulation of cerebral structures in patients with treat-
ment-resistant depression. Resting-state PET studies
and fMRI using behavioral tests have consistently re-
ported that increased pretreatment activity in the pre-
genual cingulate cortex (aCg24; Brodmann’s area 24)
distinguishes responders to a series of antidepressant
interventions from nonresponders.5,31–33 In contrast,
subgenual cingulate cortex (Cg25, Brodmann’s area 25)
hyperactivity has been shown to predict response to
sleep deprivation7 and cingulotomy34 in patients who
had previously not responded to antidepressants, thus
constituting a potential neurobiological marker of treat-
ment-resistant depression.35
Mayberg5 recently elaborated on a previously pro-
posed multinode circuit model of clinical depression
that evolved mainly from the functional neuroimaging
findings summarized above. In this model, regions of
potential involvement are grouped in four major nodes
with different roles in the onset and maintenance of, but
also in response to treatment of, depressive symptoms
(Figure 2). In this model, two of the clusters are mostly
concerned with interoceptive phenomena and the so-
matic correlates of depression (Figure 2, light gray pan-
els), and the other two clusters are concerned with ex-
teroception and neocortical processing and their
abnormalities during depressive episodes (Figure 2, dark
gray panels). As consistently observed across studies,
commencing with early functional neuroimaging reports,
reciprocal interactions between ventral limbic—“intero-
ceptive”—and dorsal neocortical—“exteroceptive”—re-
gions are characterized by relative hyperactivity of the
former and relative hypoactivity in the latter.5 Medial
PFC, including orbitofrontal structures, are considered
FIGURE 2. Model of Depressive Symptom Formation Incorporating Cognitive/”Exteroceptive” Aspects (Dark Gray Modules) and





















ACganterior cingulate cortex; a-insanterior insula; amgamygdala; BSseptal nuclei; Cgcingulate cortex; dm-Thdorsomedial
thalamus; dp-HCdorsal-posterior hippocampus; hthhypothalamus; MCgmedial cingulate cortex; mFmedial frontal cortex;
mOFmedial orbital frontal cortex; Parparietal cortex; PFCprefrontal cortex; PMpremotor cortex; va-HCventral anterior
hippocampus; vtaventral tegmental area; vst-cdventral striatum-caudate. Numbers designate cortical Brodmann’s areas.
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separately in the model to account for their distinctive role
in the cognitive control of emotional status. Similarly, sub-
cortical structures participating in cortical-limbic loops in-
volved in emotion, including amygdaloid nuclei, ventral
tegemental area, thalamic nuclei, and ventral striatal re-
gions, have been segregated from anterior insula and es-
pecially the hypothalamus, given their role in the process-
ing of novel stimuli and salience as well as in
reinforcement and therefore learning.5,36–40 The proposed
model provides a conceptual framework to understand
the rationale for using a series of DBS targets in depres-
sion. Thus, in addition to Cg25, other targets modulating
cortical-limbic circuits presumably abnormal in depres-
sion have been proposed, including anterior limb of the
internal capsule, nucleus accumbens, inferior thalamic pe-
duncle, rostral cingulate gyrus, and left forebrain activa-
tion via vagus nerve stimulation.10,39–43 However, the
model does not incorporate emerging data on an asym-
metrical role of brain hemispheres in mood regulation, as
illustrated by the case of Mr. A.
Asymmetrical Contribution of Brain Structures to the
Development of Depressive Symptoms and Response to
Treatment
The asymmetrical response of Mr. A to subcallosal cin-
gulate DBS suggests a differential contribution of left
and right prosencephalic structures in mood regulation.
Structural and functional asymmetry of the human
brain has been recognized since the second half of the
19th century due to the pioneering work of Dax,44
Broca,45 and Wernicke46 on the preeminent role of left-
sided lesions in the production of most cases of aphasia.
An additional landmark in the study of brain asymme-
try was the work of Tseng and Sperry47 and their col-
laborators with patients who had undergone surgical
transection of their corpus callosum to prevent the
propagation of seizures. This work extended the con-
cept of brain asymmetry to “higher” cognitive functions
beyond language. Studies on hemi-neglect in patients
with right-sided lesions of the brain revealed a signifi-
cant asymmetry in the neural circuits involved in the
regulation of attention to outside events, which in-
volves not only a series of sensory modalities but mo-
tivational and emotional responses to them as well.48
However, knowledge of the brain’s functional asymme-
tries and their impact on emotion and behavior is lim-
ited, in part, due to the fact that good experimental
models have been lacking until recently. This is likely,
in part, due to the view that lateralization of brain
functions and behavior has long been considered a
purely human trait.49 The seminal work of Notte-
bohm and colleagues50,51 on asymmetries in the neu-
ral control of song production in birds has modified
this perception. Subsequently, asymmetric contribu-
tions of brain hemispheres to a variety of behaviors
have been recognized as a ubiquitous feature of CNS
organization across species, including fish, birds, am-
phibians, rodents, and nonhuman primates,52 though
themes relative to “higher” cognitive functioning
have been more intensively studied than asymmetric
contributions of brain hemispheres to emotion, auto-
nomic/visceral sensation, and mood and motivated
behavior.
Nonetheless, hemispheric laterality has been a pre-
eminent theme in the field of early lesion correlation
with depression (i.e., whether left and right cerebral
structures contribute differently to dysregulation of
mood and the emergence of depressive symptoms). A
series of studies supports the hypothesis of an asym-
metrical role of the two hemispheres. The majority of
data showing a differential role of left versus right
CNS circuits in the generation of depressive symp-
toms were derived from studies investigating inci-
dent depression after a localized cerebral lesion, es-
pecially a stroke.53–56 These studies offered evidence
that left (but not right) anterior hemisphere lesions
were causally associated with depression, which was
interpreted as suggesting that dysfunction of left pre-
frontal circuits might be a feature in this disorder.
An alternative explanation, in light of more recent
studies on brain function as described below, could be
that right PFC activity might become predominant after
suffering left-sided lesions, and this imbalance instead
of left PFC dysfunction might underlie the develop-
ment of depressive symptoms. Early positron emission
tomography (PET) and electroencephalographic (EEG)
studies suggested a pronounced left PFC hypoactiv-
ity57,58 as well. However, a series of attempts at repli-
cation, as well as meta-analyses, do not support a sys-
tematic effect of lesion location on poststroke
depression.59–61 Koenigs and Grafman62 recently re-
ported on the association between left, right, or bilateral
cerebral lesions and depressive symptoms 15 and 35
years after the index brain injury in a cohort of male
Vietnam War veterans. The demographic homogeneity
of the sample permitted excellent comparability be-
tween groups and in addition with a group of veterans
who had not sustained significant brain damage. The
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study concluded that in this population in particular
there were no associations between depressive symp-
toms and side of the cerebral lesion.62 Taken together,
studies on the correlation between discrete brain lesions
and depression have not clearly demonstrated a uni-
form role of hemispheric laterality in the appearance of
depressive symptoms.
Findings of altered bilateral activity of components
of circuits involved in depression have been ob-
served, but other studies strongly suggest an asym-
metry in the contribution of anterior cortical-limbic
circuits to the appearance of depressive symptoms.
Dougherty et al.34 attempted to define potential rest-
ing-state cerebral activity predictors of response to
cingulotomy, using [18F]fluorodeoxyglucose (FDG)-
PET. The study is of particular interest because the
patients belonged, like Mr. A, to a population with
the most severe and most treatment-refractory forms
of major depressive disorder. They observed that hy-
peractivity in the left subgenual cerebral cortex and
left thalamus correlated with improvement in depres-
sive symptom severity following cingulotomy.34 In a
study exploring the relationship between changes in
cerebral metabolic activity and improvement of de-
pressive symptoms after sleep deprivation, Wu et al.7
observed that improvement in depressive symptom-
atology was correlated with an increase in the activity
of the left temporal cortex and a decrease in left
anterior medial PFC, without similar contralateral
findings. In a recent study, Konarsky et al.27 detected
an increase in glucose metabolism in Brodmann’s
areas 24 and 32, the interphase sector between “cog-
nitive” and “visceral/emotional” portions of the cin-
gulate cortex, specifically on the left side, in de-
pressed patients who had not responded to cognitive
behavior therapy (CBT) or venlafaxine treatment.
Other evidence points to a preeminent role of right
cortico-subcortical functioning in the modulation of
mood and in response to antidepressant treatment.
Kennedy et al.63 described changes in brain glucose
metabolism associated with 16-week-long treatment ei-
ther with venlafaxine or CBT. Right subgenual/ventro-
medial frontal increase in metabolism was observed in
patients responding to CBT, whereas decreases in me-
tabolism in the right posterior subgenual cingulate
were associated with response to venlafaxine. Notably,
reduction in metabolic activity bilaterally in the orbito-
frontal cortex was associated with response to either
treatment modality. In contrast, decreased metabolism
restricted to the left orbitofrontal cortex was observed
irrespective of treatment group or treatment outcome
(i.e., left hemispheric changes were irrelevant to the
response of depressive symptoms). The Kennedy et
al.63 study extends asymmetrical brain metabolic find-
ings to the right thalamus, a subcortical structure that is
a component of the circuit involved in mood regulation.
These findings, as well as the fact that Mr. A responded
to unilateral right stimulation of Brodmann’s area 25,
are also congruent with the observation that the right
dorsomedial PFC is activated relatively selectively in a
wide range of emotional tasks, including recollection of
affectively meaningful life events,64 attention to subjec-
tive feelings,65 and processing of emotion-related mean-
ings.66 In this fMRI study, healthy subjects were pre-
sented a series of pictures combined with relevant
captions resulting in positive, negative, and neutral af-
fective connotations. Presentation of negative picture-
caption pairs was associated with activation of a series
of cortical and subcortical structures, in all cases local-
ized to the right hemisphere: medial and right middle
frontal gyri (Brodmann’s area 9), right anterior cingu-
late gyrus (areas 24 and 32), and right thalamus.66
Our provisional observation of prolonged depression
remission with right, but not left, unilateral stimulation
of the subgenual cingulate cortex (Brodmann’s area 25)
is concordant with those findings in response to anti-
depressants and the induction of negative affect in
healthy individuals, and suggests that efficacy of DBS
in Mr. A was entirely explained by its effects on the
right cerebral hemisphere. Some of the implicated right-
sided structures are in the vicinity of the midline, so the
efficacy of right DBS might also be explained, at least in
part, by bilateral effects of a single electrode placed on
that side. This is best appreciated by observing the tra-
jectory of tracts in the vicinity of—and thus presumably
affected by—the DBS electrodes in Mr. A (Figure 3). As
seen in this figure, neuronal tracts affected by each
electrode show ipsilateral projections to the PFC. Tracts
neighboring the right electrode, however, seem to ad-
ditionally project contralaterally to a greater extent than
those in the vicinity of the left electrode in this patient.
This emphasizes the need to further define the tracts
critical for mood regulation67 and perhaps suggests
that, in the future, attempts at regulating brain cir-
cuits might need to be “customized” to match the
interindividual variability in anatomical projections.
This approach has already been proposed for subtha-
lamic nuclei DBS in idiopathic Parkinson’s disease.68
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Regardless of the reasons for the present observation
of asymmetric contribution of right versus left DBS to
the amelioration of depressive symptoms, Mr. A’s
case probably points to a need to take into account
hemispheric asymmetries in models of depressive
symptom generation.
If further studies confirm, that just as is the case with
attention,48 the right hemisphere serves a preeminent
role in normal mood regulation and clinical depression,
the question arises whether lateralization applies to all
components of Mayberg’s model of depression delin-
eated above5,25 or if instead “interoceptive” (subcorti-
cal/paleocortical) or “exteroceptive” (neocortical) nodes
are preferentially lateralized in their contribution to mood
regulation.
Asymmetrical Central Representation of Visceral
Function and Its Relationship With Regulation of Mood
and Emotion
There is recent evidence favoring lateralization in the con-
trol of abnormal visceral sensation in the context of mood
dysregulation. Coen et al.69 described the patterns of brain
activation during the processing of painful and nonpain-
ful visceral stimuli (esophageal distention) in different af-
fective states. Evidence for a dominant role of the right
hemisphere in the bodily correlates of negative emotion
was obtained that specifically involves the right anterior
cingulate (Brodmann’s areas 24 and 32), right anterior
insula, and inferior frontal gyrus.69 Gut sensations evok-
ing increased heart rate, low-frequency/high-frequency
heart rate variability ratio, and plasma epinephrine, an
autonomic pattern characteristically associated with de-
pression,70–73 are associated with increased activation of
right insula, right orbitofrontal cortex, and right parahip-
pocampal gyrus, as well as subcortical and brainstem
structures.74 This further suggests a right hemispheric
dominance in the control of visceral sensation associated
with negative mood and the autonomic profiles charac-
teristic of it.
Induction of negative mood has been associated with
hyperactivity of right insula and prefrontal cortical
structures in healthy volunteers as well.4 Consistent
with this view, Giesecke et al.75 observed that symp-
toms of depression correlate with pain-evoked activa-
tion of the right anterior insula. Craig76,77 summarized
evidence explaining the lateralization of emotion pro-
cessing and suggested that the right insular cortex
might be the principal CNS structure responsible for
sentience and self-consciousness. He proposed that
prosencephalic emotional asymmetry in turn reflects an
asymmetrical representation of homeostatic activity, ul-
timately explained by asymmetries in the autonomic
nervous system hierarchy including peripheral sympa-
thetic and parasympathetic structures. Vagal afferents
innervate the nucleus of the solitary tract, whereas sym-
pathetic afferents terminate in lamina I of the dorsal
horn of the spinal cord. From there, axons innervate the
basal (parasympathetic) and posterior (sympathetic)
portions of the ventromedial nucleus of the thalamus.
This topographical organization is present in primates,
and is extremely well-developed only in humans.76,78–80
Ultimately, the left anterior insula is activated by affer-
ent information related to parasympathetic functions,
whereas the right anterior insula is activated by afferent
information associated with sympathetic activity (e.g.,
FIGURE 3. Diffusion Tensor Imaging of Nerve Tracts in the
Vicinity of Electrodes Placed in the Subgenual
Cingulum in Mr. A in Coronal (Top Panel) and








Shown in dark gray are white matter tracts passing through
right-sided deep brain stimulation targets. Note that there are
ipsilateral connections to the medial orbital frontal cortex from each
side. Only the right-sided contact shows contralateral tract
involvement (white arrow). Notable also are the more lateral tracts
to the lateral prefrontal and anterior insula from the left-sided
contact (in light gray). MOFMedial orbital frontal cortex;
InsInsula; VLPFCVentral lateral prefrontal cortex.
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pain).76 Thus, activity in the right prosencephalon is
associated with energy expenditure, sympathetic activ-
ity, arousal, aversive behavior, and survival emotions,
whereas activity in the left forebrain is associated with
energy nourishment, parasympathetic activity, relax-
ation, appetitive behavior, and affiliative emotions.77
There is, in fact, a growing body of evidence that sug-
gests that left and right forebrain structures are associ-
ated with positive and negative affect, respectively.81 It
has been suggested that this, in turn, reflects asymme-
tries in autonomic afferent input onto limbic struc-
tures.82,83 The concept behind the correlation between
anatomical segregation of afferent autonomic input and
cerebral involvement in the processing of emotions is
the cornerstone of the James-Lange theory, which main-
tains that emotional feeling states are initiated by auto-
nomic afferent information reaching consciousness.84,85
This theory has received support recently because of
evidence that peripheral autonomic clues are crucial for
motivated behavior.86,87
Complete suppression of otherwise treatment-refrac-
tory depressive symptoms in Mr. A by means of right
DBS (presumably blocking neural transmission in fore-
brain limbic structures on that side88) is consistent with
this growing body of evidence on lateralization of emo-
tional regulation and also with preliminary observa-
tions that another neuromodulation tool useful in treat-
ment-resistant depression, vagus nerve stimulation,
might exert its beneficial effect via activation of left
forebrain structures and reciprocal inhibition of right
forebrain structures.39,76 Although we do not have func-
tional brain imaging studies available to demonstrate
the effects of DBS on either side of the brain in Mr. A,
we have collected data on cardiac autonomic activity in
resting conditions (Figure 4). Using analysis of heart
rate variability,89 we identified high-frequency (para-
sympathetic) and low-frequency (baroreflex, but pre-
dominantly sympathetic) influences on the sinus node
(Biomedical Signal Analysis Group, Department of Ap-
plied Physics, University of Kuopio, Finland). As
shown in Figure 4, unilateral right DBS was character-
ized by remarkably lower low-frequency/high-fre-
quency ratio (an estimation of the sympathovagal bal-
ance on the heart)89,90 than unilateral left DBS. As
expected, heart rate was higher in the latter condition,
further suggesting increased sympathetic and/or de-













































The top panels depict the duration of successive cardiac beats (RR intervals, s), and the bottom panels show the fast Fourier transform
analysis of the resulting signals (power spectral density, PSD, s2/Hz) of resting-state recordings obtained during unilateral right (A) and
unilateral left (B) stimulation of the subgenual cingulum. Low-frequency (LF) heart rate variability (0.03–0.15 Hz, light gray) reflects
baroreflex but predominantly sympathetic activity. High-frequency (HF) heart rate variability (0.15–0.4 Hz, light gray) measures respiratory
sinus arrhythmia and is therefore a specific indicator of cardiac parasympathetic activity. LF/HF ratio, a measure of sympathovagal balance
onto the heart,88,89 was higher during left than during right stimulation (8.17 vs 2.42, respectively). Most noticeable is the withdrawal of
vagal activity during left stimulation (0.15–0.4 Hz range). Accordingly, heart rate was higher in this condition (100.4 bpm vs 90.2 bpm
during right stimulation).
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creased vagal input to the heart. If confirmed, these
observations suggest that emotional well-being de-
pends not only on “top-down” but also “right-left”
modulation of prosencephalic activity, and would per-
mit reconceptualization of older studies on the effect of
brain lesions in the production of depressive symp-
toms. The common observation of left lesions being
associated with the development of depression might,
in light of this model, be explained less by the interrup-
tion of brain circuits on the left side than by unopposed
influences of right forebrain and limbic structures,
physiologically associated with negative affect, sympa-
thetic activity, and energy expenditure. Stimulation of
the unencumbered right hemisphere, resulting in inhi-
bition of local and remote structures within these cir-
cuits,1 may help to restore interhemispheric balance.
Summary and Recommendations for Future Research
Although still relatively small in number, there is bur-
geoning evidence of the efficacy of DBS in the treatment
of the most severely treatment-refractory depressed pa-
tients.10,41 The current case adds to this database, and
like previous reports it demonstrates the potential util-
ity of this intervention in those patients who have failed
to respond to past adequate treatment with psychother-
apy, a variety of antidepressants, and ECT. Although
the present observation needs to be confirmed in dou-
ble-blind studies, as Mr. A’s psychiatrist was not blind
to changes in stimulation parameters, this case raises
important questions about laterality of mood regulation
and unilateral versus bilateral DBS treatment, which
warrant further study. The present case example and
the bulk of evidence highlight the preeminence of cor-
tical and subcortical structures in the right hemisphere
in the generation and maintenance of depression. This
hypothesis remains to be confirmed with studies spe-
cifically addressing this question, including animal
models of the disease as appropriate.
Presented in part at the Annual Congress of the World
Psychiatric Association in Florence, Italy, April 1–4, 2009.
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